New Clinical Trial Data in Advanced Melanoma Presented at ASCO 2018: How Will it Change How You Practice?

Sanjiv S. Agarwala, MD

Video Categories: 2018 ASCO Insights and Video Library

Dr Sanjiv Agarwala talks about exciting new results presented at ASCO 2018 in melanoma, including the durability of anti–PD-1 therapy in providing 40% overall survival at 5 years, updates on adjuvant therapy showing superiority of anti–PD-1 over anti–CTLA-4, and new results in combining immunotherapies.

September 20, 2013

Developing an Accurate Price Model for Personalized Medicines

Randy Vogenberg discusses the complexities of developing pricing for personalized medicine products

August 29, 2018

How PD-L1 Biomarker Test Results Impact Clinical Management of Lung Cancer

Drs. Goeffrey Oxnard and Lauren Ritterhouse review how the results of PD-L1 testing influence the choices in first- or second-line immunotherapy or combination immunochemotherapy in patients with squamous or non-squamous non-small-cell lung cancer.